Literature DB >> 2245488

Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes.

M B Bally1, R Nayar, D Masin, P R Cullis, L D Mayer.   

Abstract

The myelosuppressive activity of doxorubicin encapsulated in liposomes of differing lipid composition and size was quantified in mice by measurement of changes in spleen weight, peripheral white blood cells (WBC), and bone marrow nucleated cells. Following i.v. administration of free doxorubicin at a dose of 20 mg/kg, a 90% reduction in marrow cellularity was observed on day 3. The marrow nucleated cell count was similar to control values by day 7. Administration of an equivalent dose of doxorubicin that was encapsulated in large (diameter, approximately 1.0 microns) egg phosphatidylcholine/cholesterol (EPC/Chol)(molar ratio, 55:45) liposomes induced an 80% reduction in bone marrow cellularity that lasted for periods of greater than 7 days. Similar results were obtained following administration of large (1.0 microns) liposomal doxorubicin systems formulated with distearoylphosphatidylcholine/cholesterol (DSPC/Chol) (molar ratio 55:45). In contrast, liposomal doxorubicin prepared using small (diameter, approximately 0.1 micron) DSPC/Chol liposomes induced only a 40% reduction (day 3) in bone marrow cellularity, which returned to control values by day 7. Other indicators of doxorubicin-mediated myelosuppressive activity (spleen weight loss and peripheral leukopenia) correlated well with changes observed in marrow cellularity. An exception to this, however, was observed in animals treated with small (0.1 -micron) DSPC/Chol Liposomal doxorubicin, which displayed peripheral leukopenia for periods of greater than 14 days. This extended leukopenia was not observed following administration of small (0.1 -micron) EPC/Chol liposomal doxorubicin. Marrow-associated liposomal lipid and doxorubicin were quantified to determine if the extent of doxorubicin-mediated myeloid toxicity could be correlated to changes in biodistribution of the entrapped drug. It was demonstrated that 10-20 times more doxorubicin is delivered to the bone marrow when the drug is given encapsulated in large liposomes than when it is associated with small liposomes. These data are useful in defining characteristics of liposomal preparations that modulate the myelosuppressive behaviour of entrapped antineoplastic agents.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2245488     DOI: 10.1007/bf00689270

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  21 in total

1.  Liposomes with entrapped doxorubicin exhibit extended blood residence times.

Authors:  M B Bally; R Nayar; D Masin; M J Hope; P R Cullis; L D Mayer
Journal:  Biochim Biophys Acta       Date:  1990-03-30

2.  Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.

Authors:  L D Mayer; L C Tai; D S Ko; D Masin; R S Ginsberg; P R Cullis; M B Bally
Journal:  Cancer Res       Date:  1989-11-01       Impact factor: 12.701

3.  Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient.

Authors:  L D Mayer; M B Bally; P R Cullis
Journal:  Biochim Biophys Acta       Date:  1986-05-09

Review 4.  Liposomes in vivo; conversion of liposomal cholesterol to bile salts.

Authors:  G L Scherphof; F Kuipers; J T Derksen; H H Spanjer; R J Vonk
Journal:  Biochem Soc Trans       Date:  1987-12       Impact factor: 5.407

5.  Interaction of liposomes with human leukocytes in whole blood.

Authors:  S H Kuhn; B Gemperli; E G Shephard; J R Joubert; P A Weidemann; G Weissmann; M C Finkelstein
Journal:  Biochim Biophys Acta       Date:  1983-02-16

6.  Liposomal protection of adriamycin-induced cardiotoxicity in mice.

Authors:  A Rahman; A Kessler; N More; B Sikic; G Rowden; P Woolley; P S Schein
Journal:  Cancer Res       Date:  1980-05       Impact factor: 12.701

7.  Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice.

Authors:  A Gabizon; A Dagan; D Goren; Y Barenholz; Z Fuks
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

8.  Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers.

Authors:  A Gabizon; D Goren; Z Fuks; Y Barenholz; A Dagan; A Meshorer
Journal:  Cancer Res       Date:  1983-10       Impact factor: 12.701

9.  Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin.

Authors:  J A Balazsovits; L D Mayer; M B Bally; P R Cullis; M McDonell; R S Ginsberg; R E Falk
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

10.  Immunotoxicity of multiple dosing regimens of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes.

Authors:  A Rahman; A Joher; J R Neefe
Journal:  Br J Cancer       Date:  1986-09       Impact factor: 7.640

View more
  14 in total

1.  In vitro evaluation of polymeric micelles based on hydrophobically-modified sulfated chitosan as a carrier of doxorubicin.

Authors:  Xiu-Hua Wang; Qin Tian; Wei Wang; Chuang-Nian Zhang; Ping Wang; Zhi Yuan
Journal:  J Mater Sci Mater Med       Date:  2012-04-27       Impact factor: 3.896

2.  Novel drug delivery system using thermoreversible gelation polymer for malignant glioma.

Authors:  Takao Arai; Tatsuhiro Joki; Masaharu Akiyama; Miyuki Agawa; Yuichi Mori; Hiroshi Yoshioka; Toshiaki Abe
Journal:  J Neurooncol       Date:  2006-03       Impact factor: 4.130

Review 3.  Adverse drug events related to dosage forms and delivery systems.

Authors:  I F Uchegbu; A T Florence
Journal:  Drug Saf       Date:  1996-01       Impact factor: 5.606

4.  Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin.

Authors:  B A Conley; M J Egorin; M Y Whitacre; D C Carter; E G Zuhowski; D A Van Echo
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Evaluation of triblock copolymeric micelles of δ- valerolactone and poly (ethylene glycol) as a competent vector for doxorubicin delivery against cancer.

Authors:  Lekha Nair K; Sankar Jagadeeshan; S Asha Nair; G S Vinod Kumar
Journal:  J Nanobiotechnology       Date:  2011-09-25       Impact factor: 10.435

6.  In vitro investigation of self-assembled nanoparticles based on hyaluronic acid-deoxycholic acid conjugates for controlled release doxorubicin: effect of degree of substitution of deoxycholic acid.

Authors:  Wen-Hao Wei; Xue-Meng Dong; Chen-Guang Liu
Journal:  Int J Mol Sci       Date:  2015-03-31       Impact factor: 5.923

7.  Antioxidants selenomethionine and D-pantethine decrease the negative side effects of doxorubicin in NL/Ly lymphoma-bearing mice.

Authors:  Rostyslav R Panchuk; Nadia R Skorokhyd; Yuliya S Kozak; Liliya V Lehka; Vira V Chumak; Sofya N Omelyanchik; Valery A Gurinovich; Andrey G Moiseenok; Rostyslav S Stoika
Journal:  Croat Med J       Date:  2016-04-23       Impact factor: 1.351

8.  A herbal formula, SYKT, reverses doxorubicin‑induced myelosuppression and cardiotoxicity by inhibiting ROS‑mediated apoptosis.

Authors:  Ting Chen; Hong-Mei Shen; Zhi-Yong Deng; Zuo-Zhang Yang; Rui-Lian Zhao; Li Wang; Zhi-Ping Feng; Chao Liu; Wen-Hui Li; Zhi-Jie Liu
Journal:  Mol Med Rep       Date:  2017-03-01       Impact factor: 2.952

Review 9.  Main trends of immune effects triggered by nanomedicines in preclinical studies.

Authors:  Blanka Halamoda-Kenzaoui; Susanne Bremer-Hoffmann
Journal:  Int J Nanomedicine       Date:  2018-09-17

10.  Extracellular Vesicles Released by Cardiomyocytes in a Doxorubicin-Induced Cardiac Injury Mouse Model Contain Protein Biomarkers of Early Cardiac Injury.

Authors:  Chontida Yarana; Dustin Carroll; Jing Chen; Luksana Chaiswing; Yanming Zhao; Teresa Noel; Michael Alstott; Younsoo Bae; Emily V Dressler; Jeffrey A Moscow; D Allan Butterfield; Haining Zhu; Daret K St Clair
Journal:  Clin Cancer Res       Date:  2017-10-25       Impact factor: 13.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.